Recent findings published by Pharmacy Times highlight Elinzanetant as a promising non-hormonal treatment option for menopausal vasomotor symptoms. Elinzanetant distinguishes itself by offering a safe and well-tolerated alternative for those seeking relief from symptoms such as hot flashes and night sweats, which often accompany menopause. This new therapy stands out particularly because it avoids the hormonal approach traditionally used, thereby being suitable for individuals unable to use hormone replacement therapies. Clinical trials have demonstrated Elinzanetant’s effectiveness and minimal side effects, positioning it ideally for broad usage. As more women seek non-hormonal solutions for menopausal management, Elinzanetant’s emergence could significantly impact how symptoms are treated globally. This advancement marks a crucial development in women’s health, offering hope to millions experiencing menopausal discomfort.
Pharmacy TimesNew data shows an 18% drop in suicide rates since 988 launch
June 24, 2026
A new report reveals an encouraging 18% decrease in suicide rates across the United States since the introduction of the 988 Suicide & Crisis Lifeline.